CD274 and neoplasm: Based on our previous finding that Roscovitine decreases PD-L1 in tumor cells (12), we hypothesized that it would enhance the sensitivity to anti-PD-1, at least in part by increasing the immune response by specifically decreasing PD-L1 levels.